Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Real-world treatment patterns, outcomes, and unmet needs in patients with ph+ ALL receiving tyrosine kinase inhibitors in the United States: Emerging trends and the role of asciminib-based combinations

Marlise Luskin, Andrea Damon, Emily McGovern, Dominick Latremouille-Viau, Annie Guerin, Carmine Rossi, Fredrick Kinkhead, Gabriel Marquez, David Wei, Islam Mohamad Sadek, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5097.

https://doi.org/10.1182/blood-2025-5097

Published: 2025

Journal Articles

Indirect treatment comparison (ITC) of asciminib and dasatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)

Onyee Chan, Gabriel Marquez, Valentine Laizet, Rob Mingxin Liu, Gabriela Friedrich, Katerina Papadimitropoulou, Isabelle Lundqvist, Shaun Walsh, Emily McGovern, Islam Mohamad Sadek, David Wei

Blood (2025) 146 (Supplement 1): 4611.

https://doi.org/10.1182/blood-2025-4611

Published: 2025

Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Blood (2025) 146 (Supplement 1): 5549.

https://doi.org/10.1182/blood-2025-5549

Published: 2025

Journal Articles

Treatment cost per AE symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia

Jennifer Vaughn, Nadine Zawadzki, Caroline Hardy, Gabriel Marquez, Gopi Madhav Bommidi, Poornima Sachin Dhobe, Sai Vasmi Gedala, Islam Mohamad Sadek, Jason Shafrin, David Wei

Blood (2025) 146 (Supplement 1): 2835.

https://doi.org/10.1182/blood-2025-2835

Published: 2025

Journal Articles

Real-world analysis of asciminib as first-line therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A chart review Study in the United States

Ehab Atallah, Islam Mohamad Sadek, Emily McGovern, Dominick Latremouille-Viau, Carmine Rossi, Remi Bellefleur, Gabriel Marquez, Annie Guerin, Daisy Yang, David Wei

Blood (2025) 146 (Supplement 1): 8178.

https://doi.org/10.1182/blood-2025-8178

Published: 2025

Journal Articles

The humanistic burden of patients with chronic myeloid leukemia (CML) treated with first line (1L) tyrosine kinase inhibitors (TKIs)

Kelly Schoenbeck, Joan Clements, Karen Demairo, David Wei, Nisha Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Gabriel Marquez, Daisy Yang, Andrea Damon, Islam Mohamad Sadek, Annie Guerin, Kathryn Flynn

Blood (2025) 146 (Supplement 1): 6388.

https://doi.org/10.1182/blood-2025-6388

Published: 2025

Journal Articles

A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase

Ehab Atallah, Islam Mohamad Sadek, Emily McGovern, Dominick Latremouille-Viau, Carmine Rossi, Remi Bellefleur, Nathan Gobeil, Gabriel Marquez, Annie Guerin, Daisy Yang, David Wei

Blood (2025) 146 (Supplement 1): 724.

https://doi.org/10.1182/blood-2025-724

Published: 2025

Journal Articles

Real-World Treatment Patterns and Molecular Response (MR) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting

Ira Zackon, April Beeks, David Wei, Chuck Wentworth, Jinhong Guo, Courtney McDermott, Kejal Jadhav, Lisa Herms, Andrea Damon, Islam Sadek, Christopher B. Benton

Blood (2024) 144 (Supplement 1): 6611.

https://doi.org/10.1182/blood-2024-210681

Published: 2024

Journal Articles

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

Kelly Schoenbeck, Joan Clements, Karen Demairo, David Wei, Nisha C Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Kejal Jadhav, Courtney McDermott, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guerin, Kathryn E. Flynn

Blood (2024) 144 (Supplement 1): 7913.

https://doi.org/10.1182/blood-2024-207213

Published: 2024

Journal Articles

Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis

Gaurav Vadnerkar, Joan Clements, Mel Mann, Vainavika Reddy Gaddam, Chaitali Nag, Shiva Padhi, David Wei, Marcello Azolino, Kejal Jadhav, Daisy Yang, Andrea Damon, Islam Sadek

Blood (2024) 144 (Supplement 1): 5192.

https://doi.org/10.1182/blood-2024-199951

Published: 2024

Journal Articles

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Elias Jabbour, David Wei, Hongbo Yang, Kejal Jadhav, Wei Song, Yajin Zhao, Anran Shao, Samantha Tomicki, Daisy Yang, Andrea Damon, Islam Sadek, Vamsi K. Kota

Blood (2024) 144 (Supplement 1): 2434.

https://doi.org/10.1182/blood-2024-201831

Published: 2024

Journal Articles

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

Ehab L. Atallah, Islam Sadek, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Daisy Yang, Remi Bellefleur, Annie Guérin, Kejal Jadhav

Blood (2024) 144 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2024-193201

Published: 2024

Journal Articles

Financial Impact of Treatment Choice in CML: A Comparison of Later Generation TKIs Versus Imatinib for US Patients and Payers

Jason Shafrin, Nadine Zawadzki, Shurui Zhang, Paul Pinkston, David Wei, Jennifer E Vaughn

Blood (2024) 144 (Supplement 1): 3677.

https://doi.org/10.1182/blood-2024-201000

Published: 2024

Journal Articles

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice

Ehab L. Atallah, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Germano Ferreira, Annie Guerin, Kejal Jadhav

Blood (2023) 142 (Supplement 1): 1809.

https://doi.org/10.1182/blood-2023-178722

Published: 2023

Journal Articles

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav

Blood (2023) 142 (Supplement 1): 5098.

https://doi.org/10.1182/blood-2023-180772

Published: 2023

Journal Articles

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav

Blood (2023) 142 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2023-180789

Published: 2023

Journal Articles

Recurrent and Refractory Hemophagocytic Lymphohistiocytosis in an Elderly. Role of Immune Aberration Due to Myeloid Gene Mutation

Suthanthira kannan Ramamoorthy, MDFRCPA,FRCP, Tina Noutsos, BS,MBBS,FRACP,FRCPA, David Wei, MBBS,FRCPA, Alexandra Yasmin Laidman, MBBS, Ferenc Szabo, FRACP,FRCPA

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-133776

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real-world treatment patterns, outcomes, and unmet needs in patients with ph+ ALL receiving tyrosine kinase inhibitors in the United States: Emerging trends and the role of asciminib-based combinations

Indirect treatment comparison (ITC) of asciminib and dasatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Treatment cost per AE symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia

Real-world analysis of asciminib as first-line therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A chart review Study in the United States

The humanistic burden of patients with chronic myeloid leukemia (CML) treated with first line (1L) tyrosine kinase inhibitors (TKIs)

A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase

Real-World Treatment Patterns and Molecular Response (MR) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting

Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study

Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

Financial Impact of Treatment Choice in CML: A Comparison of Later Generation TKIs Versus Imatinib for US Patients and Payers

Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Recurrent and Refractory Hemophagocytic Lymphohistiocytosis in an Elderly. Role of Immune Aberration Due to Myeloid Gene Mutation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only